4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the

Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit

LISLE, Ill., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Amy M. Dodrill has been appointed to its board of directors, effective February 8, 2024, and will serve as a member of the nominating, governance and sustainability and technology and transactions committees. Ms. Dodrill comes to CTS with over 25 years of experience in medical and technology companies and a proven track record of successfully leading and profitably growing global businesses serving key end markets. Ms. Dodrill most recently served as President of Baxter's Global Surgical

Neptune Medical, a leading innovator in medical technology, is pleased to announce the appointment of Dr. Fred Moll as Chairman of the Board. Dr. Moll, a seasoned entrepreneur and influential figure in the medical technology industry considered to be the father of medical robotics, brings a wealth of experience and expertise to Neptune Medical. Dr. Fred Moll is currently a Managing Partner at Sonder Capital, a venture capital firm focused on investing in breakthrough healthcare technologies. His illustrious career includes founding Intuitive Surgical, a pioneer in robotic-assisted minimally invasive surgery, and Auris Health, which was acquired by Johnson & Johnson. In addition to his r

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Mary Garrett to its Board of Directors. Ms. Garrett most recently served on the board of Hillrom Corporation which was acquired by Baxter International Inc. in December 2021. Ms. Garrett was the governance committee chair and served on the audit committee of Hill-Rom. She also previously served as a board member and was on the audit committee of Ethan Allen Interiors, Inc. Prior to these roles and her retirement in 2015, Ms. Garrett was the

REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Elisabeth Sandoval to its Board of Directors. Ms. Sandoval currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Intersect ENT, Inc., Satsuma Pharmaceuticals, Inc. and Vyne Therapeutics, Inc. She is also on the Board of privately held Alastin Skincare. Ms. Sandoval previously served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy at Alder Biopharmaceuti

SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy

SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Members of PROCEPT BioRobotics' management team presenting include: Reza Zadno – Chief Executive OfficerKevin Waters – Chief Financial OfficerSham Shiblaq – Chief Commercial OfficerBarry Templin – Chief Technology Officer Clinical perspectives will also be

SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue of approximately $68.2 million for the fourth quarter of 2024, an increase of 57% compared to the prior year periodU.S. system revenue of $27.6 million for the fourth quarter of 2024, an increase of 67% compared to the prior year periodSold 60 new robotic systems in the U.S. in the fourth quarter of 2024 at a blended average selling price of a

SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2024 after market close on Tuesday, February 25, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/q33jvv92 Dial-in registration for sell-side research analysts

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $58.4 million for the third quarter of 2024, an increase of 66% compared to the prior period in 2023U.S. handpiece and consumables revenue of $29.6 million for the third quarter of 2024, an increase of 74% compared to the prior period in 2023Sold 45 robotic systems in the U.S. in the third quarter of 2024

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/yhamkcsz Dial-in registration for sell-side re

SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes. "We are pleased to bring the H

SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023U.S. handpiece and consumables revenue of $27.3 million for the second quarter of 2024, an increase of 101% compared to the prior period in 2023Sold 47 robotic systems in the U.S. in the second quarter of 2024U.S. system and rental revenue of $17.

SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/qsztnzfu/ Dial-in registration for sell-side research

SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Recent Highlights Total revenue of $44.5 million for the first quarter of 2024, an increase of 83% compared to the prior year period in 2023U.S. handpiece and consumables revenue of $23.6 million for the first quarter of 2024, an increase of 101% compared to the prior year period in 2023Sold 38 U.S. robotic systems in the first quarter of 2024U.S. system and rental revenue of